近11亿美元！A股“药王”，再获海外创新药大单

Core Viewpoint - Heng Rui Medicine has secured significant overseas innovation drug contracts, indicating strong international interest in its proprietary drugs and a strategic focus on global market expansion [2][5][16]. Group 1: Recent Developments - On September 24, Heng Rui Medicine announced a licensing agreement for its innovative drug SHR-A1811 with Glenmark Specialty, receiving an upfront payment of $18 million and potential milestone payments up to $1.093 billion [2][11]. - This marks the second major overseas deal for Heng Rui Medicine in September, following a $65 million upfront payment agreement with Braveheart Bio for the HRS-1893 project, with potential milestone payments up to $1.013 billion [5][18]. Group 2: Product Details - SHR-A1811 is an antibody-drug conjugate targeting HER2, designed to induce apoptosis in tumor cells by releasing toxins upon internalization [11][12]. - The drug is set to be approved for use in non-small cell lung cancer (NSCLC) patients with HER2 mutations by May 2025, and it has received orphan drug designation from the FDA for gastric cancer indications [12][13]. Group 3: Strategic Partnerships - Heng Rui Medicine is committed to a dual strategy of independent research and open collaboration, enhancing its international partnerships to maximize product value and integrate into the global drug innovation network [16]. - Glenmark Specialty, part of Glenmark Pharmaceuticals, is a research-driven global pharmaceutical company with a focus on respiratory, dermatology, and oncology treatments, operating in over 80 countries [16].